Siraj Omar Wali1, Bahaa Abaalkhail2, Faris Alhejaili3, S R Pandi-Perumal4. 1. Sleep Medicine Research Group, Sleep Medicine and Research Center, College of Medicine, King Abdulaziz University Hospital, P.O. Box 21589, Jeddah, 80215, Saudi Arabia. sowali@kau.edu.sa. 2. Family and Community Medicine Department, Faculty of Medicine, King Abdulaziz University, Jeddah, Saudi Arabia. 3. Sleep Medicine Research Group, Sleep Medicine and Research Center, College of Medicine, King Abdulaziz University Hospital, P.O. Box 21589, Jeddah, 80215, Saudi Arabia. 4. Somnogen Canada Inc., College Street, Toronto, ON, Canada.
Abstract
PURPOSE:Restless legs syndrome is a movement sleep disorder that may be linked to dopaminergic dysfunction and in which vitamin D may play a role. This 12-week randomized, placebo-controlled trial elucidated the efficacy of vitamin D supplements in decreasing restless legs syndrome symptom severity. METHODS:Thirty-five subjects with restless legs syndrome, diagnosed using the International Restless Legs Syndrome Study Group criteria, were enrolled. The subjects were randomized to orally receive either vitamin D (50,000 IU caplets) or a placebo. All medications were administered weekly using a direct observation technique. Clinical assessments, including those for restless legs syndrome severity, were conducted at baseline and the end of the study using the International Restless Legs Syndrome Study Group rating scale. The serum vitamin D levels and bone profiles were measured at baseline and every 4 weeks. The primary endpoint was the change in the restless legs syndrome severity score from baseline to week 12. There were 17 and 18 patients in the vitamin D and placebo groups, respectively. RESULTS: The groups did not differ with respect to age, sex, restless legs syndrome severity, or vitamin D levels. Participants in the vitamin D group showed no significant change in the mean restless legs syndrome severity score compared with the placebo group. CONCLUSIONS: The results suggest that vitamin D supplementation does not improve restless legs syndrome symptoms. CLINICAL TRIAL REGISTRATION NUMBER: ClinicalTrials.gov : NCT02256215 (available from: https://clinicaltrials.gov/ct2/show/NCT02256215 ).
RCT Entities:
PURPOSE:Restless legs syndrome is a movement sleep disorder that may be linked to dopaminergic dysfunction and in which vitamin D may play a role. This 12-week randomized, placebo-controlled trial elucidated the efficacy of vitamin D supplements in decreasing restless legs syndrome symptom severity. METHODS: Thirty-five subjects with restless legs syndrome, diagnosed using the International Restless Legs Syndrome Study Group criteria, were enrolled. The subjects were randomized to orally receive either vitamin D (50,000 IU caplets) or a placebo. All medications were administered weekly using a direct observation technique. Clinical assessments, including those for restless legs syndrome severity, were conducted at baseline and the end of the study using the International Restless Legs Syndrome Study Group rating scale. The serum vitamin D levels and bone profiles were measured at baseline and every 4 weeks. The primary endpoint was the change in the restless legs syndrome severity score from baseline to week 12. There were 17 and 18 patients in the vitamin D and placebo groups, respectively. RESULTS: The groups did not differ with respect to age, sex, restless legs syndrome severity, or vitamin D levels. Participants in the vitamin D group showed no significant change in the mean restless legs syndrome severity score compared with the placebo group. CONCLUSIONS: The results suggest that vitamin D supplementation does not improve restless legs syndrome symptoms. CLINICAL TRIAL REGISTRATION NUMBER: ClinicalTrials.gov : NCT02256215 (available from: https://clinicaltrials.gov/ct2/show/NCT02256215 ).
Entities:
Keywords:
Primary; RLS; Restless legs syndrome; Scale; Symptoms; Vitamin D
Authors: Richard P Allen; Arthur S Walters; Jacques Montplaisir; Wayne Hening; Andrew Myers; Timothy J Bell; Luigi Ferini-Strambi Journal: Arch Intern Med Date: 2005-06-13
Authors: M Ibi; H Sawada; M Nakanishi; T Kume; H Katsuki; S Kaneko; S Shimohama; A Akaike Journal: Neuropharmacology Date: 2001-05 Impact factor: 5.250
Authors: T C Wetter; K Stiasny; J Winkelmann; A Buhlinger; U Brandenburg; T Penzel; R Medori; M Rubin; W H Oertel; C Trenkwalder Journal: Neurology Date: 1999-03-23 Impact factor: 9.910
Authors: Richard P Allen; Daniel Picchietti; Wayne A Hening; Claudia Trenkwalder; Arthur S Walters; Jacques Montplaisi Journal: Sleep Med Date: 2003-03 Impact factor: 3.492
Authors: Arthur S Walters; Cheryl LeBrocq; Anjana Dhar; Wayne Hening; Ray Rosen; Richard P Allen; Claudia Trenkwalder Journal: Sleep Med Date: 2003-03 Impact factor: 3.492